AZ 960

News alerts, weekly reports and conference planners

Company:

AstraZeneca, Qiagen

Drug class:

JAK2 inhibitor

Related drugs:

MMP11 overexpression	Breast Cancer	MMP11 overexpression	Breast Cancer	GDC-0941 + AZ 960 Sensitive: C3 – Early Trials GDC-0941 + AZ 960 Sensitive : C3	GDC-0941 + AZ 960 Sensitive: C3 – Early Trials GDC-0941 + AZ 960 Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	AZ 960 Sensitive: C3 – Early Trials AZ 960 Sensitive : C3	AZ 960 Sensitive: C3 – Early Trials AZ 960 Sensitive : C3

Associations
(2)